International Journal of Frontiers in Medicine, 2023, 5(10); doi: 10.25236/IJFM.2023.051016.
Li Li, Yaning Zhu, Nan Zhou, Tongfei Yang, Hang Feng, Xianpeng Shi, Peng Zhang
Pharmacy Department, Shaanxi Provincial People's Hospital, Xi'an, China
Pediatric epilepsy ranks among the most prevalent neurological disorders in children. The efficacy of sodium valproate in treating epilepsy is closely tied to its serum concentration, which exhibits substantial inter-individual variability. This study investigates the alterations in gut microbiota in pediatric epilepsy patients across various age groups following the administration of sodium valproate. The findings reveal a trend of decreased relative abundance of Bacteroides and Blautia in fecal samples with increasing age, coupled with an elevation in the abundance of Ruminococcus. Consequently, it is postulated that the primary factor initiating differences in sodium valproate concentration among pediatric epilepsy patients across different age groups is associated with changes in gut microbiota. Understanding the impact of gut microbiota on sodium valproate concentration is crucial for guiding the pharmacological treatment of epilepsy in affected children.
Pediatric Epilepsy; Sodium Valproate Concentration; Gut Microbiota; Different Age Groups
Li Li, Yaning Zhu, Nan Zhou, Tongfei Yang, Hang Feng, Xianpeng Shi, Peng Zhang. Impact of Intestinal Microbiota Disparities on Sodium Valproate Concentrations in Pediatric Epileptic Patients. International Journal of Frontiers in Medicine (2023), Vol. 5, Issue 10: 102-106. https://doi.org/10.25236/IJFM.2023.051016.
[1] Gonzalez-Viana E., Sen A., Bonnon A., Cross J. H., Guideline Committee. (2022) Epilepsies in children, young people, and adults: summary of updated NICE guidance. BMJ, 7, 378
[2] Pediatric Status Epilepticus Collaborative Group. (2022) Chinese Expert Consensus on the Diagnosis and Treatment of Status Epilepticus in Children. Journal of Epilepsy, 05, 383-389.
[3] Wang Y., Hu W., Li Z. (2020) Influence of age and co-medication on the concentration and efficacy of valproic acid in Chinese epilepsy children. Pak J Pharm Sci, 33, 537-542.
[4] Yue Q., Cai M., Xiao B., Zhan Q., Zeng C. (2021) The Microbiota-Gut-Brain Axis and Epilepsy. Cell Mol Neurobiol, 42, 439-453.
[5] Zhai J., Wang C., Jin L., Liu F., Xiao Y., Gu H., Liu M., Chen Y. (2023) Gut Microbiota Metabolites Mediate Bax to Reduce Neuronal Apoptosis via cGAS/STING Axis in Epilepsy. Mol Neurobiol, 08, 22.
[6] Fisher R.S., Acevedo C, Arzimanoglou A. (2014) ILAE official report: a practical clinical definition of epilepsy. Epilepsia, 55, 475-482.
[7] Bhandary S., Aguan K. (2015) Pyruvate dehydrogenase complex deficiency and its relationship with epilepsy frequency-An overview. Epilepsy Res, 116, 40-52.
[8] Chu X.M., Zhang L.F., Wang G.J., Zhang S.N., Zhou J. H., Hao H. P. (2012) Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients. Eur J Clin Pharmacol, 68, 1395-401.
[9] Hu H., Shao W., Liu Q., Liu N., Wang Q., Xu J., Zhang X., Weng Z., Lu Q., Jiao L., Chen C., Sun H., Jiang Z., Zhang X., Gu A. (2022) Gut microbiota promotes cholesterol gallstone formation by modulating bile acid composition and biliary cholesterol secretion. Nat Commun, 13, 252.